Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, Bradbury P, Moskovitz M, Katgi N, Tomasini P, Zer A, Girard N, Cuppens K, Han JY, Wu SY, Baijal S, Mansfield AS, Kuo CH, Nishino K, Lee SH, Planchard D, Baik C, Li M, Ansell P, Xia S, Bolotin E, Looman J, Ratajczak C, Lu S.
European Respiratory Society clinical practice guideline for the management of adult bronchiectasis.
Chalmers JD, Haworth CS, Flume P, Long MB, Burgel PR, Dimakou K, Blasi F, Herrero-Cortina B, Dhar R, Chotirmall SH, Ringshausen FC, Altenburg J, Morgan L, Nigro M, Crichton ML, Van Meel C, Sibila O, Timothy A, Kompatsiari E, Hedberg T, Vandendriessche T, McShane PJ, Tonia T, Winthrop K, Loebinger MR, Lorent N, Goeminne P, Shteinberg M, Polverino E, Aliberti S.
Eur Respir J. 2025 Dec 18;66(6):2501126. doi: 10.1183/13993003.01126-2025. Print 2025 Dec.
PMID:41016738
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D.
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV.
J Clin Oncol. 2019 Jun 20;37(18):1558-1565. doi: 10.1200/JCO.19.00201. Epub 2019 May 8.
PMID:31067138
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.
Machtay M, Torres-Saavedra PA, Thorstad W, Nguyen-Tân PF, Siu LL, Holsinger FC, El-Naggar A, Chung C, Cmelak A, Burtness B, Bednarz G, Quon H, Breen SL, Gwede CK, Dicker AP, Yao M, Jordan RC, Dorth J, Lee N, Chan JW, Dunlap N, Bar-Ad V, Stokes WA, Chakravarti A, Sher D, Rao S, Harris J, Yom SS, Le QT; NRG Oncology RTOG 0920 Collaborating Team.
Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma.
Lee NY, Sherman EJ, Schöder H, Wray R, Boyle JO, Singh B, Grkovski M, Paudyal R, Cunningham L, Zhang Z, Hatzoglou V, Katabi N, Diplas BH, Han J, Imber BS, Pham K, Yu Y, Zakeri K, McBride SM, Kang JJ, Tsai CJ, Chen LC, Gelblum DY, Shah JP, Ganly I, Cohen MA, Cracchiolo JR, Morris LGT, Dunn LA, Michel LS, Fetten JV, Kripani A, Pfister DG, Ho AL, Shukla-Dave A, Humm JL, Powell SN, Li BT, Reis-Filho JS, Diaz LA, Wong RJ, Riaz N.
J Clin Oncol. 2024 Mar 10;42(8):940-950. doi: 10.1200/JCO.23.01308. Epub 2024 Jan 19.
PMID:38241600
A foundation model for clinical-grade computational pathology and rare cancers detection.
Vorontsov E, Bozkurt A, Casson A, Shaikovski G, Zelechowski M, Severson K, Zimmermann E, Hall J, Tenenholtz N, Fusi N, Yang E, Mathieu P, van Eck A, Lee D, Viret J, Robert E, Wang YK, Kunz JD, Lee MCH, Bernhard JH, Godrich RA, Oakley G, Millar E, Hanna M, Wen H, Retamero JA, Moye WA, Yousfi R, Kanan C, Klimstra DS, Rothrock B, Liu S, Fuchs TJ.